Latest tools for COVID-19 Omicron variant research

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein.

Latest tools for COVID-19 Omicron variant research

Image Credit: AMS Biotechnology

AMSBIO’s new Spike neutralizing monoclonal antibodies (clone G10xA5 and G10xA1) recognize the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralize its interaction with ACE2. Both these neutralizing antibodies have been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit.

Also new is AMSBIO’s Spike S1 RBD: ACE2 Inhibitor Screening Assay Kit. This key colorimetric assay kit is designed for screening and profiling inhibitors or neutralizing antibodies of the interaction between the Omicron variant SARS-CoV-2 Spike RBD and human ACE2. The new assay requires only a few steps to use. Firstly, SARS-CoV-2 Spike RBD (B.1.1.529, Omicron variant) is coated on a 96-well plate overnight. After washing and blocking, the protein is pre-incubated with an inhibitor or neutralizing antibody. Following incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP then addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.

Since the beginning of the global pandemic - several new SARS-CoV-2 variants have emerged, each with differing mutations that impact transmissibility, COVID-19 disease severity, and the effectiveness of vaccines. AMSBIO now offers a series of recombinant antigens and pseudotyped lentivirus with key Spike mutations in order to evaluate the efficacy of antibodies and vaccines. These products form part of a larger COVID-19 Tools for Research portfolio, including other high quality recombinant proteins, Spike pseudotyped lentivirus, and reagents for vaccine development and evaluation.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2022, January 11). Latest tools for COVID-19 Omicron variant research. News-Medical. Retrieved on January 19, 2022 from https://www.news-medical.net/news/20220111/Latest-tools-for-COVID-19-Omicron-variant-research.aspx.

  • MLA

    AMS Biotechnology. "Latest tools for COVID-19 Omicron variant research". News-Medical. 19 January 2022. <https://www.news-medical.net/news/20220111/Latest-tools-for-COVID-19-Omicron-variant-research.aspx>.

  • Chicago

    AMS Biotechnology. "Latest tools for COVID-19 Omicron variant research". News-Medical. https://www.news-medical.net/news/20220111/Latest-tools-for-COVID-19-Omicron-variant-research.aspx. (accessed January 19, 2022).

  • Harvard

    AMS Biotechnology. 2022. Latest tools for COVID-19 Omicron variant research. News-Medical, viewed 19 January 2022, https://www.news-medical.net/news/20220111/Latest-tools-for-COVID-19-Omicron-variant-research.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Highly Efficient Exosome Isolation & Purification Tools